These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 15651751)

  • 1. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
    Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
    Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.
    Yao FY; Osorio RW; Roberts JP; Poordad FF; Briceno MN; Garcia-Kennedy R; Gish RR
    Liver Transpl Surg; 1999 Nov; 5(6):491-6. PubMed ID: 10545536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
    van Nunen AB; de Man RA; Heijtink RA; Vossen AC; Schalm SW
    J Viral Hepat; 2002 May; 9(3):221-8. PubMed ID: 12010511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
    Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
    Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.
    Lu AW; Zheng SS; Wu MP; Shen Y; Yang RW
    Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):357-61. PubMed ID: 18693169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence.
    Powell JJ; Apiratpracha W; Partovi N; Erb SR; Scudamore CH; Steinbrecher UP; Buczkowski AK; Chung SW; Yoshida EM
    Clin Transplant; 2006; 20(4):524-5. PubMed ID: 16842532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
    Dickson RC; Terrault NA; Ishitani M; Reddy KR; Sheiner P; Luketic V; Soldevila-Pico C; Fried M; Jensen D; Brown RS; Horwith G; Brundage R; Lok A
    Liver Transpl; 2006 Jan; 12(1):124-33. PubMed ID: 16382463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.
    Buti M; Mas A; Prieto M; Casafont F; González A; Miras M; Herrero JI; Jardí R; Cruz de Castro E; García-Rey C
    J Hepatol; 2003 Jun; 38(6):811-7. PubMed ID: 12763375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B prophylaxis in living donor liver transplantation: single center experience.
    Yaprak O; Dayangac M; Balci D; Bas K; Yuzer Y; Tokat Y
    Hepatogastroenterology; 2010; 57(102-103):1178-82. PubMed ID: 21410054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.